Impact of FDG-PET/CT on Management of Patients with Native Valve Infective Endocarditis

Launched by MONTREAL HEART INSTITUTE · Mar 9, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how a special imaging test called FDG-PET/CT can help doctors manage patients suspected of having native valve infective endocarditis (NVE), which is an infection affecting the heart's valves. The trial is taking place at six different medical centers and is looking to understand if this imaging can improve diagnosis and treatment decisions for patients who meet certain criteria, known as the modified Duke criteria.

To participate in the study, individuals must be at least 18 years old, able to give consent, and have been referred for the FDG-PET/CT test because they are suspected of having possible infective endocarditis. However, individuals with artificial heart valves, those who are pregnant or breastfeeding, and those with a very high body weight (BMI over 45) cannot participate. If eligible, participants can expect to undergo the FDG-PET/CT scan, which is non-invasive, and their results may help guide their treatment plan. The trial is currently recruiting participants, and everyone is welcome regardless of gender.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years of age or older, capable to provide informed consent;
• • Referred for a FDG-PET/CT study
• • Classified as having Possible IE prior to FDG-PET/CT imaging;
• • Patients must be able to tolerate the physical/logistical requirements of a PET/CT scan.
• Exclusion Criteria:
• • Subjects with prosthetic cardiac valve and/or CIED;
• • Pregnant or breastfeeding female;
• • Body mass index \> 45 kg/m2.